Skip to main content

Table 2 Indications of sirolimus therapy

From: Proteinuria and baseline renal function predict mortality and renal outcomes after sirolimus therapy in liver transplantation recipients

Variable N (%)
Renal dysfunctiona 318 (55.2)
HCC  
 Prophylaxis 93 (16.1)
 Recurrence 21 (3.6)
Non-hepatic tumors 18 (3.1)
Biopsy proved acute/chronic rejection 84 (14.6)
Neurotoxicity 5 (0.9)
Other side effects from immunosuppressants 37 (6.4)
  1. aDefined by physician’s criteria or eGFR <60 mL/min/1.73 m2 without other reasons for SRL use